Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions. In ...

Are they destined to change the future of pharma? Nominate a colleague with impressive leadership and career intentions ...

Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions.

Reuters benchmarking versus UK NHS payouts showed ~33% of sampled TrumpRx-listed drugs were cheaper in the UK, with 67%–82% ...

In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two ...

Founder, Infinitus touches on the approach to human oversight in an effort to build trust in autonomous patient access workflows by keeping humans and AI in a continuous feedback loop. In a ...

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...

One key failure mechanism is the logistic implementation for the DCT trials. A lot of times, when you go to a global trial, there's a lot of logistic management for DCT. Let's say you must ship the ...

Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...

Matthew Turner, President of Patient Affordability, Paysign discusses how next-generation copay assistance appears to be less about consolidating services under one vendor and more about assembling ...